Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA Income Statement 2011-2026 | BPTS

Annual Income Statement Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 549 M - - - - - - - - - -

Shares

- - 118 M - - - - - - - - - -

Historical Prices

0.33 1.43 4.64 - - - - - - - - - -

Net Income

- - -31.2 M -17.1 M -17.8 M -14 M -11.4 M -7.95 M -3.29 M -709 K -522 K - -

Operating Income

- - -26.8 M -13.9 M -15.7 M -13.9 M - - - - - - -

EBITDA

- - -26.8 M -13.9 M -15.7 M -13.9 M -9.7 M -7.77 M -3.12 M -659 K -468 K - -

General and Administrative Expenses

- - 7.15 M 4.02 M 4.6 M 4.35 M 2.86 M 2.82 M 2.07 M 373 K 396 K - -

All numbers in EUR currency

Quarterly Income Statement Biophytis SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Biophytis SA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.49 0.58 % $ 1.04 B canadaCanada
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
argenx SE argenx SE
ARGX
$ 700.45 -1.19 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.6 1.41 % $ 8.66 B australiaAustralia
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.81 -2.01 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 225.98 -1.32 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.13 -5.06 % $ 105 M schweizSchweiz
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
$ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.19 1.21 % $ 27.2 B germanyGermany
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 7.92 1.67 % $ 1.31 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
$ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.6 -4.0 % $ 7.83 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA